Humacyte (NASDAQ:HUMA) Shares Up 6% – What’s Next?

Humacyte, Inc. (NASDAQ:HUMA)’s stock price was up 6% during trading on Thursday . The stock traded as high as $4.79 and last traded at $4.78. Approximately 920,995 shares traded hands during mid-day trading, a decline of 67% from the average daily volume of 2,770,237 shares. The stock had previously closed at $4.51.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on HUMA. Benchmark boosted their price objective on Humacyte from $15.00 to $17.00 and gave the stock a “buy” rating in a research note on Monday, December 23rd. D. Boral Capital reaffirmed a “buy” rating and set a $25.00 target price on shares of Humacyte in a research note on Friday, December 20th. HC Wainwright reissued a “buy” rating and issued a $15.00 price target (up previously from $12.00) on shares of Humacyte in a research note on Friday, December 20th. BTIG Research reaffirmed a “buy” rating and set a $10.00 price target on shares of Humacyte in a research report on Friday, October 18th. Finally, TD Cowen reiterated a “buy” rating and issued a $10.00 price objective on shares of Humacyte in a research report on Friday, October 18th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $13.71.

Humacyte Price Performance

The company has a fifty day moving average of $4.77 and a 200-day moving average of $5.77. The company has a current ratio of 1.10, a quick ratio of 1.10 and a debt-to-equity ratio of 0.61. The stock has a market cap of $692.22 million, a PE ratio of -4.10 and a beta of 1.38.

Insider Buying and Selling at Humacyte

In other Humacyte news, CEO Laura E. Niklason sold 811,172 shares of the business’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $4.44, for a total value of $3,601,603.68. Following the completion of the transaction, the chief executive officer now owns 2,419,712 shares in the company, valued at $10,743,521.28. The trade was a 25.11 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Brady W. Dougan sold 427,459 shares of the stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total value of $1,855,172.06. Following the completion of the sale, the director now owns 1,992,253 shares in the company, valued at approximately $8,646,378.02. The trade was a 17.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,500,000 shares of company stock valued at $6,606,799 in the last three months. 11.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Humacyte

A number of institutional investors and hedge funds have recently made changes to their positions in HUMA. nVerses Capital LLC acquired a new stake in Humacyte in the second quarter valued at approximately $28,000. Concurrent Investment Advisors LLC purchased a new position in Humacyte in the third quarter valued at $75,000. Principal Financial Group Inc. purchased a new stake in Humacyte during the 2nd quarter worth about $83,000. FORA Capital LLC acquired a new position in shares of Humacyte during the 3rd quarter worth about $96,000. Finally, Insigneo Advisory Services LLC purchased a new position in shares of Humacyte in the 3rd quarter valued at about $109,000. 44.71% of the stock is owned by institutional investors and hedge funds.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.